CD Flex: An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex vs. Long Flex] in Subjects with Cervical Dystonia < 10 Weeks of Benefit from OnabotulinumtoxinA Treatment
ID Number 13-0118Principal Investigator(s)
Department(s) or Division(s)
The purpose of this research study is to compare Xeomin® (incobotulinumtoxinA), a botulinum toxin treatment, in shorter injection intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) to determine if more frequent dosing leads to development of botulinim toxin resistance. The Parkinson and Movement Disorder Center at Mount Sinai is looking for individuals over the age of 18 with cervical dystonia to participate in this study.
Recruiting Patients: Yes